VERU [NASD]
Veru Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own19.49% Shs Outstand80.05M Perf Week-4.11%
Market Cap1.01B Forward P/E- EPS next Y-0.46 Insider Trans0.00% Shs Float60.00M Perf Month6.30%
Income-27.50M PEG- EPS next Q-0.18 Inst Own28.70% Short Float27.86% Perf Quarter129.52%
Sales60.50M P/S16.73 EPS this Y131.00% Inst Trans-2.61% Short Ratio0.72 Perf Half Y65.12%
Book/sh1.70 P/B7.55 EPS next Y-27.30% ROA-15.70% Target Price34.00 Perf Year45.30%
Cash/sh1.42 P/C9.04 EPS next 5Y- ROE-18.60% 52W Range4.34 - 17.50 Perf YTD117.83%
Dividend- P/FCF- EPS past 5Y49.20% ROI9.80% 52W High-26.69% Beta-0.57
Dividend %- Quick Ratio6.30 Sales past 5Y22.60% Gross Margin81.40% 52W Low195.62% ATR1.83
Employees252 Current Ratio6.60 Sales Q/Q-2.30% Oper. Margin-35.60% RSI (14)55.26 Volatility11.78% 17.14%
OptionableYes Debt/Eq0.11 EPS Q/Q-367.80% Profit Margin-45.60% Rel Volume0.26 Prev Close12.64
ShortableYes LT Debt/Eq0.08 EarningsMay 24 BMO Payout- Avg Volume23.08M Price12.83
Recom1.60 SMA2012.92% SMA5034.92% SMA20066.18% Volume6,067,257 Change1.50%
Apr-13-21Initiated Jefferies Buy $19
Feb-09-21Reiterated H.C. Wainwright Buy $12 → $17
Jan-21-20Reiterated H.C. Wainwright Buy $4.50 → $6
Mar-20-19Initiated Oppenheimer Outperform $5
Jul-03-18Initiated Maxim Group Buy
May-25-22 08:30AM  
May-18-22 08:30AM  
May-17-22 12:37PM  
08:30AM  
May-16-22 01:26PM  
May-13-22 12:45PM  
10:08AM  
May-12-22 07:45AM  
06:30AM  
May-11-22 08:23AM  
06:40AM  
06:30AM  
May-10-22 04:32PM  
May-09-22 09:30AM  
May-05-22 06:15PM  
03:00PM  
May-04-22 10:53AM  
May-02-22 05:33PM  
08:30AM  
Apr-28-22 08:30AM  
Apr-26-22 10:46AM  
Apr-25-22 08:30AM  
Apr-21-22 07:55AM  
Apr-16-22 06:30AM  
Apr-14-22 09:57AM  
08:50AM  
Apr-13-22 05:36PM  
02:39PM  
11:49AM  
Apr-12-22 04:07PM  
03:35PM  
10:21AM  
06:13AM  
Apr-11-22 11:03PM  
05:48PM  
03:49PM  
01:33PM  
01:08PM  
10:41AM  
07:57AM  
06:30AM  
04:05AM  
Mar-04-22 08:30AM  
Mar-01-22 08:30AM  
Feb-17-22 08:30AM  
Feb-14-22 08:30AM  
Feb-12-22 08:30AM  
Feb-09-22 07:45AM  
06:30AM  
Feb-08-22 10:00AM  
Feb-02-22 03:01PM  
Feb-01-22 08:30AM  
Jan-31-22 08:30AM  
Jan-26-22 08:30AM  
Jan-12-22 11:39AM  
Jan-11-22 06:55PM  
09:15AM  
Jan-10-22 08:30AM  
Jan-03-22 08:30AM  
Dec-16-21 06:38PM  
Dec-14-21 12:38AM  
Dec-13-21 01:49PM  
08:30AM  
Dec-08-21 08:00AM  
Dec-02-21 10:20AM  
06:30AM  
Nov-25-21 03:00PM  
Nov-22-21 11:02AM  
Nov-18-21 08:30AM  
08:00AM  
Nov-08-21 08:30AM  
Oct-13-21 08:30AM  
Sep-21-21 12:08PM  
Sep-20-21 08:30AM  
Sep-09-21 08:30AM  
Sep-08-21 08:30AM  
Sep-02-21 03:44PM  
Aug-27-21 04:25PM  
Aug-24-21 03:53PM  
Aug-12-21 07:55AM  
06:30AM  
Aug-05-21 03:01PM  
Jul-29-21 08:30AM  
Jul-23-21 08:06AM  
Jul-16-21 09:05AM  
Jun-28-21 08:30AM  
Jun-25-21 08:30AM  
Jun-10-21 08:30AM  
Jun-08-21 09:13AM  
Jun-07-21 10:35AM  
08:30AM  
08:15AM  
May-25-21 08:30AM  
May-24-21 08:30AM  
May-19-21 12:55PM  
08:30AM  
May-12-21 10:31AM  
06:30AM  
06:15AM  
May-10-21 10:46AM  
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lu LucyDirectorAug 17Buy6.784,80032,5429,800Aug 19 01:02 PM
FISCH HARRYDirectorJun 16Sale8.35100,000835,300764,025Jun 21 12:51 PM